Q-omics provides the consensus-scored EXOC3 profile across patient tissues and cancer cell-line models. EXOC3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EXOC3 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, EXOC3 protein abundance shows 21,707 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, and PDAC as cancer lineages where EXOC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EXOC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EXOC3 survival associations across molecular data types. EXOC3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EXOC3 RNA expression–survival associations across cancer types. High EXOC3 expression shows unfavorable associations in LIHC, UVM and KICH, but favorable associations in KIRC, HNSC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EXOC3 RNA expression.
This table summarizes EXOC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for EXOC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EXOC3 shows lower tumor expression in KICH and BLCA and higher tumor expression in KIRC, HNSC, LIHC and COAD. The KIRC box plot shows higher EXOC3 RNA expression in tumor versus normal tissue (log2 FC = +0.965, t-test p < 0.001).
This table shows molecular features associated with EXOC3 in patient tissues and cancer cell lines. In patient samples, EXOC3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, EXOC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and CNS.
